Antacids Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Antacids Market, Dosage Form

7.1.  Antacids Market, Dosage Form, 2021-2028

7.1.1.    Tablet

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Liquid

7.1.2.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Antacids Market, Distribution Channel

8.1.  Antacids Market, Distribution Channel, 2021-2028

8.1.1.    Retail Pharmacy

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Hospital Pharmacy

8.1.2.1.        Market Revenue and Forecast (2016-2028)

8.1.3.    Online Pharmacy

8.1.3.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Antacids Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, Dosage Form (2016-2028)

9.1.2.    Market Revenue and Forecast, Distribution Channel (2016-2028)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.1.3.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.1.4.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, Dosage Form (2016-2028)

9.2.2.    Market Revenue and Forecast, Distribution Channel (2016-2028)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.2.3.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.2.4.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.2.5.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.2.6.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, Dosage Form (2016-2028)

9.3.2.    Market Revenue and Forecast, Distribution Channel (2016-2028)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.3.3.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.3.4.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.3.5.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.3.6.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, Dosage Form (2016-2028)

9.4.2.    Market Revenue and Forecast, Distribution Channel (2016-2028)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.4.3.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.4.4.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.4.5.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.4.6.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, Dosage Form (2016-2028)

9.5.2.    Market Revenue and Forecast, Distribution Channel (2016-2028)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.5.3.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, Dosage Form (2016-2028)

9.5.4.2.        Market Revenue and Forecast, Distribution Channel (2016-2028)

Chapter 10.  Company Profiles

10.1.              GlaxoSmithKline plc

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Bayer AG

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Boehringer Ingelheim International GmbH

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Dr. Reddy’s Laboratories Ltd.

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Sanofi

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Reckitt Benckiser Group plc;

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Sun Pharmaceuticals Ltd.

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Takeda Pharmaceutical Company Limited

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Pfizer Inc.

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Procter & Gamble

10.10.1.               Company Overview

10.10.2.               Product Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms